Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at TroVax for ovarian cancer, primary peritoneal cancer and fallopian tube cancer that has come back (TRIOC)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a vaccine called TroVax for the following cancers that have come back after initial treatment
More about this trial
Doctors initially treat these cancers with surgery and chemotherapy. After treatment, you may have blood tests to look for a marker called
TroVax helps the immune system to recognise and attack cancer cells. Many cancer cells carry a protein called 5T4. In this trial, researchers want to find out if TroVax helps the immune system to recognise 5T4 and attack cancer cells that carry this protein.
The aim of this trial is to find out if giving TroVax after a rise in CA125 can slow the growth of cancer and delay the start of chemotherapy.
Who can enter
You may be able to enter this trial if
- You have epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer that is stage 1c, 2 or 3 or stage 4a
- Your CA125 level is at least twice the upper normal level or your CA125 is above the normal level and there is a small amount of cancer can be seen on a
CT scan– your doctor can tell you this
- Your initial treatment was surgery to remove your ovaries, fallopian tubes, womb and abdominal lining
- You had chemotherapy after surgery that included a drug from the group called
platinum drugs– if you have had other chemotherapy after your initial treatment and there was no sign of your cancer after treatment (a complete response) you may be able to take part
- Your CA125 levels were normal after your platinum drug chemotherapy – your doctor can tell you this
- Your doctor thinks your cancer may be coming back because your CA125 levels are high but doesn’t recommend chemotherapy yet because you don’t have symptoms
- Your immune system is working properly
- You have satisfactory blood test results
- You are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
- You are at least 18 years old
You cannot enter this trial if
- You have a type of cancer called carcinosarcoma or mixed mullerian – your doctor can tell you this
- Your doctor feels you need to start chemotherapy immediately due to symptoms or what they see on a CT scan
- Your cancer has spread to certain areas in the liver or spleen - your doctor can tell you this
- You have a build up of fluid in the abdomen (ascites) that night need to be drained within the next 2 months
- You have a build up of fluid between the sheets of skin which cover the lungs (pleural effusion) that might need to be drained within the next 2 months
- You have had cancer treatment in the past 4 weeks or are currently having treatment
- You have had steroids for more than 4 weeks apart from inhalers and nasal sprays
- You have been taking corticosteroids for the past 6 months or more unless you are taking them due to a problem with your
adrenal glands. If you have previously taken corticosteriods for 6 months or more you may be able to take part if you stopped taking them at least 3 months before being put into one of the groups in this trial
- You are taking medication that damps down your immune system or your immune system isn’t working properly
- You have had another cancer in the past 3 years apart from non melanoma skin cancer
- You are taking
complementary medicinesthat could affect you taking part in this trial
- You are HIV, hepatitis B or hepatitis C positive
- You have any other medical condition that could affect you taking part in this trial
- You are allergic to eggs or the smallpox vaccine
- You have cancer that has spread to your brain or spinal cord
This is a phase 2 trial. It will recruit about 100 people.
This was a randomised trial. The people who agreed to take part between 2013 and 2016 were put into treatment groups by a computer. Neither they nor their doctor decided which group they were in. And neither knew which group they were in. This was a double blind trial. Half the people had TroVax. The other half had a dummy drug (placebo).
The researchers now have enough people in the placebo group. Everyone taking part now will have TroVax.
You have TroVax or the dummy drug as an injection into the muscle at the top of your arm. On each visit the opposite arm is used from the time before. You have a total of injections over 25 weeks (about 6 months). You continue treatment as long as it is helping you and the side effects aren’t too bad.
The trial team will ask you to fill out a questionnaire
- Before you start treatment
- When you have the 3rd injection and then at every injection
- After you finish treatment
- 5 and 11 months after you have finished treatment
The questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.
If you agree to take part in this study, the researchers will ask for extra blood samples during treatment and a sample of your cancer that was removed when you had surgery.
You see the doctor to have some tests before taking part in this trial. These test include
The treatment lasts about 6 months. During this time, you go to the hospital at least 8 times. You have regular blood tests and 2 more scans.
After treatment you see the doctor after
- 1 month
- 2 months – you have a scan at this visit
- Every 3 months for a year – you have a scan at each of these visits
- Every 6 months for 2 years
TroVax is a new drug and there may be side effects we don’t know about yet. The possible side effects include
- Pain, itching and swelling at the injection site (or nearby
- High temperature (fever) or chills
- Flu like symptoms
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Agnieszka Michael
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University College London (UCL)
This is Cancer Research UK trial number CRUKE/11/059.